Abstract:Gambogenic acid (GNA), which possesses diverse anti-tumor activities both in vitro and in vivo, is regarded as a potential anticancer compound. However, the excessive irritation to the blood vessel, short elimination half-life and poor aqueous solubility restricted its clinical application. In this study, Gambogenic acid-loaded PEGylated liposomes (GNA-PEG-LPs) were developed to reduce toxicity, prolong the half-life and enhance anticancer efficacy both in vitro and in vivo. The average particle size of GNA-PEG-LPs was 90.13 ± 0.16 nm and their polydispersity index (PDI) was 0.092 ± 0.003. The encapsulation efficiency, drug loading and zeta potential of GNA-PEG-LPs were 88.13 ± 1.31%, 3.72 ± 0.04%, -22.10 ± 0.20 mV, respectively. Compared to free GNA, GNA-PEG-LPs showed enhanced cytotoxicity and apoptosis induction effect against A549, SGC-7901 and HepG2 cells. Mechanistically, western blot analysis revealed that up-regulation of Bax, down-regulation of Bcl-2 and activation of caspase-3 contributed to apoptosis. In addition, the blood vessel irritation test showed that the vascular irritation of GNA could be reduced by liposomal encapsulation. The hemolysis assay revealed that good hemocompatibility of the liposomes. Furthermore, pharmacokinetic study showed that the t1/2 and the AUC of GNA-PEG-LPs were higher than GNA solution approximately 2.84-fold and 2.97-fold, respectively. In vivo antitumor efficacy demonstrated that GNA-PEG-LPs significantly inhibited the tumor growth in LLC tumor-bearing C57BL/6 mouse model. Results of Immunohistochemistry indicated that GNA-PEG-LPs significantly suppressed the expression of Bcl-2 and increased the expression of Bax and caspase-3 compared with free GNA. Collectively, PEGylated liposomes could be a potential nanocarrier to prolong half-life, reduce toxicity and enhance anticancer efficacy both in vitro and in vivo.

Pharmacolcinetics, Tissue Distribution, Excretion, and Metabolism of A Novel Antitumor Agent, Gambogenic Acid, in Rats

Assessments of Stability and Pharmacokinetics of Gambogenic Acid in Rats

Pharmacokinetics, Tissue Distribution and Excretion of Gambogic Acid in Rats

Anti-tumor Effect of Gambogenic Acid and Its Effect on CYP2C and CYP3A after Oral Administration.

Studies on the toxicity of gambogic acid in rats.

UHPLC-MS Method for Determination of Gambogic Acid and Application to Bioavailability, Pharmacokinetics, Excretion and Tissue Distribution in Rats.

Toxicological Studies of Gambogic Acid and Its Potential Targets in Experimental Animals

Structure elucidation of metabolites of gambogic acid in vivo in rat bile by high-performance liquid chromatography-mass spectrometry and high-performance liquid chromatography-nuclear magnetic resonance.

General Pharmacological Properties, Developmental Toxicity, and Analgesic Activity of Gambogic Acid, a Novel Natural Anticancer Agent

PEGylated liposomes as delivery systems for Gambogenic acid: Characterization and in vitro/in vivo evaluation

Gambogenic acid inhibits proliferation of A549 cells through apoptosis-inducing and cell cycle arresting.

Identification and quantitative determination of a major circulating metabolite of gambogic acid in human.

Differential Apoptotic Induction of Gambogic Acid, a Novel Anticancer Natural Product, on Hepatoma Cells and Normal Hepatocytes.

A novel drug delivery system of mixed micelles based on poly(ethylene glycol)-poly(lactide) and poly(ethylene glycol)-poly(ɛ-caprolactone) for gambogenic acid.

Metabolism and Metabolic Inhibition of Gambogic Acid in Rat Liver Microsomes

Gambogenic Acid Inhibits Proliferation of A549 Cells Through Apoptosis Inducing Through Up-Regulation of the P38 MAPK Cascade

Studies on Chemical Modification and Biology of a Natural Product, Gambogic Acid (III): Determination of the Essential Pharmacophore for Biological Activity

Modified Chitosan Derivative Micelle System for Natural Anti-Tumor Product Gambogic Acid Delivery

Study on Intestinal Absorption Kinetics of Gambogic Acid in Rats

Unveiling Gambogenic Acid as a Promising Antitumor Compound: A Review

Pharmacokinetics and Tissue Distribution Study of Gambogic Acid and Gambogic Acid Nanosuspension in Mice by UHPLC-MS/MS